ライフサイエンスコーパス: dyspareunia

1 vaginal narrowing, severe vaginal pain, and dyspareunia.

2 y decrease occurrence of vaginal dryness and dyspareunia.

3 h history of pelvic inflammatory disease and dyspareunia.

4 cm [95% CI, -0.49 to 0.30 cm]; P = .60), or dyspareunia (0.18 cm [95% CI, -0.22 to 0.62 cm]; P = .40

5 oskeletal problems (1.15 vs 1.10, P = .002), dyspareunia (0.78 vs 0.68, P<.001), and weight gain (0.8

6 pain 10 days after delivery and superficial dyspareunia 3 months postpartum.

7 design found that FGM/C was associated with dyspareunia (6,283 FGM/C and 3,382 non-FGM/C participant

8 Secondary symptoms were dyspareunia, abnormal vaginal discharge, chronic pelvic

9 lar in the two groups, with the exception of dyspareunia; among 290 women responding to a validated q

10 dysmenorrhea, chronic pelvic pain, and deep dyspareunia and answered questions about postoperative c

11 (dryness, itching, irritation, soreness, or dyspareunia) and clinical atrophy.

12 dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia, and 26% report infertility.

13 mbryo transfer, with worsening dysmenorrhea, dyspareunia, and overall pelvic pain.

14 nal mesh extrusion and erosion and increased dyspareunia, and pelvic pain.

15 dren presented with intermenstrual bleeding, dyspareunia, and pelvic pain.

16 roup reported more musculoskeletal problems, dyspareunia, and weight gain.

17 Vaginal dryness and dyspareunia are significant estrogen-depletion symptoms

18 Women reported no difference in superficial dyspareunia at 3 months for the continuous vs the interr

19 Breast cancer survivors with menopausal dyspareunia can have comfortable intercourse after apply

20 garding potential long-term outcomes such as dyspareunia, chronic pelvic pain, and vaginal distortion

21 The rate of frequent dyspareunia dropped significantly from 18.6% before hyst

22 Secondary outcomes were deep dyspareunia, dysmenorrhea, dyschezia, and back pain at f

23 an animal model of endometriosis-associated dyspareunia, even beyond treatment cessation.

24 substantially ameliorate vaginal dryness and dyspareunia in breast cancer survivors.

25 Dyspareunia is common in breast cancer survivors because

26 This study explored whether dyspareunia is introital pain, preventable with analgesi

27 ther assessed subjective outcomes, including dyspareunia (mean [SD] difference, -4.3 [3.4] vs -4.5 [2

28 cal evidence of severe vulvovaginal atrophy, dyspareunia (median pain score, 8 of 10; interquartile r

29 ations such as de-novo urgency, erosion, and dyspareunia need to be assessed.

30 for the therapeutic treatment of the vaginal dyspareunia of menopause in women for whom systemic estr

31 elvic pain (with or without dysmenorrhoea or dyspareunia) of at least 3 months duration.

32 nts such as infection, urinary retention, or dyspareunia or other pain, excluding mesh complications,

33 OR], 1.02; 95% CI, 1.00-1.03; P = .02), deep dyspareunia (OR, 1.03; 95% CI, 1.01-1.04; P = .004), dys

34 nal discharge (OR, 3.2; 95% CI, 2.2-4.8) and dyspareunia (OR, 2.5; 95% CI, 1.4-4.6); and factors indi

35 king AIs with self-reported vaginal dryness, dyspareunia, or decreased libido were randomized to 12 w

36 esult in improvements in pain, dysmenorrhea, dyspareunia, or quality of life compared with laparoscop

37 e as likely as non-FGM/C women to experience dyspareunia, perineal tears, prolonged labor, and episio

38 Average dyspareunia scores also improved by 41% and 60%, respect

39 depression was associated with experiencing dyspareunia, vaginal dryness, low libido, and not experi

40 f efficacy included a visual analog scale of dyspareunia, vaginal pH, a Vaginal Health Index, quality

41 ity of patients with GSM symptoms, including dyspareunia, vulvovaginal atrophy, and recurrent urinary

42 Dyspareunia was also common.

43 men responding to a validated questionnaire, dyspareunia was reported by 11.7% in the mini-sling grou

44 of pain (noncyclical pain, dysmenorrhea, and dyspareunia) were analyzed separately as was the worst p

45 atients complained about vaginal dryness and dyspareunia with impairment in sexual activity.